FinTechFunding

Antisense Therapeutics: Shares rise on long COVID-19 study

Antisense Therapeutics Shares rise on long COVID-19 study

  • Antisense Therapeutics (ANP) announces the outcomes of its collaboration to study the neurological aspects of long COVID-19 in patients who hadn’t been hospitalised
  • Blood samples were collected and used to generate data on up to 7000 proteins in the blood using the proteomics protein analysis
  • Data identified a number of proteins that can be used as diagnostic markers which could help identify neuro long COVID patients for better designed clinical trials
  • Antisense plans to review new patent applications in the US with targeted pharmaceutical and diagnostic companies for potential commercial discussions
  • ANP shares are up 18.2 per cent on the market to trade at 13 cents as of 1:42 pm AEST
Previous article
X2M Connect: Completes $3.97m entitlement offer
Next article
Meson: Raises $4M in Funding
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Regulators Strengthen Global Crackdown on Finfluencers

A new collaborative approach targets financial influencers amid rising concerns.Highlights: Financial regulators unite to control finfluencers' market impact.Concerns...
FinTech

ECB Strengthens Digital Euro Rollout with Standard Setter Agreements

New collaborations aim to facilitate the digital euro's global integration.Highlights: ECB partners with key global standard setters.Agreements aim...
FinTech

CreditNature Strengthens Nature Restoration Funding Through Everyday Transactions

New partnership enables businesses to support environmental initiatives seamlessly.Highlights: CreditNature teams up with Stabiliti for eco-friendly funding.Businesses can...
FinTech

FedNow Strengthens Instant Payments Security with New API Tool

New API tool enhances security for immediate digital transactions in the U.S.Highlights: FedNow introduces a new API tool...